117
Views
6
CrossRef citations to date
0
Altmetric
Review

Therapeutic potential of melatonin agonists

, , , &
Pages 269-279 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Daniel P. Cardinali. (2019) Melatonin as a chronobiotic/cytoprotector: its role in healthy aging. Biological Rhythm Research 50:1, pages 28-45.
Read now

Articles from other publishers (5)

Santiago Pérez-Lloret & Daniel P. Cardinali. (2021) Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson’s Disease. Frontiers in Pharmacology 12.
Crossref
Daniel P. Cardinali & Daniel E. Vigo. 2021. Psychiatry and Neuroscience Update. Psychiatry and Neuroscience Update 279 302 .
Daniel P. Cardinali. (2019) Melatonin: Clinical Perspectives in Neurodegeneration. Frontiers in Endocrinology 10.
Crossref
Daniel P. Cardinali, Venkataramanujan Srinivasan, Amnon Brzezinski & Gregory M. Brown. (2012) Melatonin and its analogs in insomnia and depression. Journal of Pineal Research 52:4, pages 365-375.
Crossref
Seithikurippu R. Pandi-Perumal, Adam Moscovitch, Venkatramanujam Srinivasan, David Warren Spence, Daniel P. Cardinali & Gregory M. Brown. (2009) Bidirectional communication between sleep and circadian rhythms and its implications for depression: Lessons from agomelatine. Progress in Neurobiology 88:4, pages 264-271.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.